PEGY
Pineapple Energy Inc. Common Stock
stock NASDAQ

Intuitive Surgical (ISRG) isn’t just another med‑tech name, it’s the company that helped turn robotic assisted surgery from a niche idea into a standard of care. Behind the da Vinci system is a powerful business model: hospitals buy the platform, then keep paying for instruments, services, and upgrades. That recurring revenue stream, combined with a growing procedure count and next‑gen platforms like da Vinci 5 and Ion, is the core of ISRG’s strategy. Looking ahead, the playbook is about expanding globally, increasing procedures per system, and embedding robotics deeper into hospital workflows potentially with more AI‑driven tools, imaging integrations, and value‑based contracts.
Collaborations already span major health systems, training centers, and technology partners. In the future, expect ISRG to lean even harder into ecosystem plays: integrating with diagnostics, data platforms, and possibly payer models that reward better outcomes and lower complications areas where robotics can genuinely move the needle.
Now, the numbers I’m working with. Using data from Yahoo Finance:
Price around $369.83
•P/E Ratio (TTM)= 49.51 and the EPS (TTM)= $8.70
• 2 years growth rate (2023–2025) of 25.08%.
That gives a PEG= 1.97. With 0% dividend, PEGY= PEG= 1.97, which, by classic rules of thumb, looks OVERVALUED unless growth surprises to the upside.
On the forward side, I used a Forward P/E (2026E) of 30.40 and Forward EPS (2026E) between 10.66 and 11.08. Multiplying them gives my estimated fair value range: Low $324 | Mid $328 | High $336.83. Versus today’s price $370, that’s a noticeable premium to my model.
Based on this setup, my quick call: short term → down; long term → up.
Price action over the past months has been volatile: a strong run to the highs, then a pullback and consolidation, with the stock moving in a range as investors weigh growth visibility against valuation and broader med‑tech rotation.
If you’re holding or watching ISRG, what’s your key assumption: faster procedure growth, higher margins, or multiple persistence that justifies paying 35–45× earnings in a higher‑for‑longer rate world?
!!!NOT A FINANCIAL ADVICE!!!

Intuitive Surgical (ISRG) isn’t just another med‑tech name, it’s the company that helped turn robotic assisted surgery from a niche idea into a standard of care. Behind the da Vinci system is a powerful business model: hospitals buy the platform, then keep paying for instruments, services, and upgrades. That recurring revenue stream, combined with a growing procedure count and next‑gen platforms like da Vinci 5 and Ion, is the core of ISRG’s strategy. Looking ahead, the playbook is about expanding globally, increasing procedures per system, and embedding robotics deeper into hospital workflows potentially with more AI‑driven tools, imaging integrations, and value‑based contracts.
Collaborations already span major health systems, training centers, and technology partners. In the future, expect ISRG to lean even harder into ecosystem plays: integrating with diagnostics, data platforms, and possibly payer models that reward better outcomes and lower complications areas where robotics can genuinely move the needle.
Now, the numbers I’m working with. Using data from Yahoo Finance:
Price around $369.83
•P/E Ratio (TTM)= 49.51 and the EPS (TTM)= $8.70
• 2 years growth rate (2023–2025) of 25.08%.
That gives a PEG= 1.97. With 0% dividend, PEGY= PEG= 1.97, which, by classic rules of thumb, looks OVERVALUED unless growth surprises to the upside.
On the forward side, I used a Forward P/E (2026E) of 30.40 and Forward EPS (2026E) between 10.66 and 11.08. Multiplying them gives my estimated fair value range: Low $324 | Mid $328 | High $336.83. Versus today’s price $370, that’s a noticeable premium to my model.
Based on this setup, my quick call: short term → down; long term → up.
Price action over the past months has been volatile: a strong run to the highs, then a pullback and consolidation, with the stock moving in a range as investors weigh growth visibility against valuation and broader med‑tech rotation.
If you’re holding or watching ISRG, what’s your key assumption: faster procedure growth, higher margins, or multiple persistence that justifies paying 35–45× earnings in a higher‑for‑longer rate world?
!!!NOT A FINANCIAL ADVICE!!!